Statement of Principles concerning malignant neoplasm of the thyroid gland (Balance of Probabilities) (No. 40 of 2022)

The instrument defines several key concepts that govern its application.

Malignant neoplasm of the thyroid gland is the central condition. It is a primary malignant neoplasm arising from follicular epithelial cells, not from other cell types. The definition expressly excludes medullary thyroid carcinoma (a neuroendocrine tumour), lymphoma, and sarcoma. That exclusion matters because medullary carcinoma has a different aetiology (often genetic) and would not be covered by the listed factors. The instrument also includes “thyroid neoplasms of uncertain malignant potential”, which are borderline lesions that may behave malignantly. The ICD‑10‑AM code C73 is assigned for statistical purposes but the substantive meaning is that in subsection 7(2).

Relevant service is defined in the Schedule 1 Dictionary as three categories: (a) eligible war service (other than operational service) under the VEA; (b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; and (c) peacetime service under the MRCA. This definition is narrower than the full range of service covered by the VEA and MRCA. Veterans who rendered operational service or hazardous service are not captured by this instrument; they would instead be assessed under the reasonable hypothesis standard and the corresponding Statement of Principles made under subsection 196B(2). The distinction reflects the different standards of proof applied by the two Acts.

Cumulative equivalent dose is a technical measure of ionising radiation exposure to a specific organ or tissue. It is the total dose from external and internal sources, excluding normal Australian background radiation. The calculation methodology is fixed to a guide published by the Australian Radiation Protection and Nuclear Safety Agency as in force on 2 August 2017. That guide is not reproduced in the instrument, so applicants and decision‑makers must locate and apply that separate document. The note lists examples of exposure sources: nuclear weapons testing, diagnostic or therapeutic medical procedures, and aircrew cosmic radiation. The dose is an average over the mass of the relevant tissue; if a tissue receives multiple radiation types, estimates must be combined.

Being obese means having a Body Mass Index of 30 or greater. BMI is defined as weight in kilograms divided by height in metres squared. This is a purely anthropometric measure and does not account for body composition or distribution of fat. Factor 9(4) requires obesity to have existed for at least 10 years before the clinical onset of the cancer.

Specified list of thyroid conditions includes goitre, Graves disease, Hashimoto thyroiditis, hyperthyroidism, and thyrotoxicosis. These are benign thyroid disorders that may increase the risk of malignant transformation.

Acromegaly is defined as a chronic disease from excess growth hormone after epiphyseal closure. Organ or tissue transplantation excludes corneal transplant but includes all or part of an organ or tissue or a substance obtained from one. Terminal event is defined as the proximate or ultimate cause of death and includes pneumonia, respiratory failure, cardiac arrest, circulatory failure, or cessation of brain function.

The direct subjects of this instrument are veterans and members of the Australian Defence Force who have rendered “relevant service” as defined, and who claim compensation for malignant neoplasm of the thyroid gland under the VEA or the MRCA. Specifically, it affects those whose service is eligible war service (non‑operational), defence service (non‑hazardous, non‑British nuclear test), or peacetime service under the MRCA. That excludes the bulk of veterans with combat service or hazardous service, who would use a different standard and likely a different Statement of Principles. The instrument also indirectly affects the dependants of such persons who may claim in relation to a death contributed to by thyroid cancer, because the definition of malignant neoplasm includes death from a terminal event contributed to by the cancer.

The primary decision‑makers who apply this instrument are the Repatriation Commission, the Military Rehabilitation and Compensation Commission, and the Veterans’ Review Board. They must use the factors as a minimum causation template. Medical practitioners who provide evidence in support of claims are also affected, because they must be able to speak to the existence and duration of factors such as cumulative radiation dose, obesity, thyroid conditions, acromegaly, and transplantation history. The instrument imposes no duties on these medical professionals directly, but in practice they must tailor their reports to the definitions and timeframes the instrument prescribes.

Legal practitioners representing claimants must understand the definitional exclusions. For example, a claimant with medullary thyroid carcinoma cannot satisfy the definition of malignant neoplasm of the thyroid gland under this instrument and must instead find a different causation basis, possibly under a general residual provision or another Statement of Principles. Similarly, a claimant who underwent iodine‑131 therapy for an unrelated thyroid condition must show that the therapy occurred at least five years before clinical onset. The instrument also affects the Repatriation Medical Authority itself, which must periodically review the scientific literature and update the factors. This instrument updates the 2014 version, indicating a continuing process.

The instrument creates no new duties on individuals. It is a binding standard for decision‑makers. The Repatriation Medical Authority had the duty to determine the factors based on sound medical‑scientific evidence, and it states at section 8 that it has done so. The Authority also had the duty to specify the kind of disease, to define relevant terms, and to repeal the earlier instrument.

For claimants, the key right is to have a claim for malignant neoplasm of the thyroid gland assessed by reference to the factors in section 9. If a claimant can prove, on the balance of probabilities, that at least one factor exists and that the factor is related to their relevant service, then the decision‑maker must find that the condition is service‑related. That finding then entitles the claimant to compensation under the relevant Act, subject to other eligibility criteria. The instrument does not itself create that entitlement; it merely establishes the causation bridge.

Claimants also have the right to rely on the note examples in the cumulative equivalent dose definition. For example, a claimant who was present as an Australian participant in nuclear weapons tests can argue that exposure falls within the note. However, the note is illustrative, not exhaustive, and does not create a presumption. The claimant must still prove the dose using the ARPANSA methodology.

The duty of decision‑makers is to apply the factors strictly. They cannot add or remove factors not listed. They must also apply section 11 if a factor refers to another disorder covered by a separate Statement of Principles. That means if a claimant satisfies factor 9(7) (organ transplantation) and the underlying reason for the transplant is a kidney disease covered by another Statement of Principles, the factors of that other instrument become relevant. This can create a chain of causation that the decision‑maker must trace.

No duty exists on the Authority or the Commission to proactively inform claimants of the existence of the instrument. It is for the claimant to produce evidence that meets the factors. The instrument does not confer a right to a particular medical expert or to a particular method of proof.

This instrument does not itself impose penalties. It is a rule of substantive law about causation, not a prohibition or an offence provision. Enforcement of the compensation scheme lies elsewhere. However, the VEA and the MRCA contain criminal penalties for making false or misleading statements in connection with a claim. A person who knowingly fabricates a radiation dose history or falsifies a medical record to satisfy a factor under this instrument could be prosecuted under those Acts. The instrument does not reference those penalties, but they are a backdrop.

The Repatriation Medical Authority is not an enforcement body. It sets the standards. The Commission and the Board enforce compliance with the instrument through their decision‑making processes. If a decision‑maker fails to apply the instrument correctly, the claimant can seek merits review at the Veterans’ Review Board and further review at the Administrative Appeals Tribunal or the Federal Court on a question of law. The instrument is therefore judicially reviewable, though its content is treated as a legislative instrument and typically not open to challenge on the merits unless it is beyond power or procedurally flawed.

The instrument has no compliance burden in the ordinary sense for businesses or the public. The compliance burden falls on the veteran or member who must assemble evidence. For example, proving a cumulative equivalent dose of 0.5 sievert to the thyroid may require obtaining military service records, medical imaging history, and possibly a dose reconstruction by a health physicist. That is a costly and time‑consuming process. The instrument does not provide any mechanism for the government to bear that cost; the claimant must pay or rely on free assistance from advocacy organisations.

The instrument also imposes an evidentiary burden in the sense that a decision‑maker may reject a claim if the evidence does not meet the precise thresholds. For instance, a claimant who was obese for nine years and 11 months before onset, rather than ten years, would not satisfy factor 9(4). That kind of technicality can lead to a denial even if obesity was likely a contributing factor. The instrument does not allow a sliding scale or a “substantially similar” alternative.

This instrument operates within the broader framework of the Veterans’ Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. It is made under subsection 196B(3) of the VEA, which deals with statements of principles for the balance of probabilities standard. That subsection is one of four: subsection 196B(2) for reasonable hypothesis; subsection 196B(3) for balance of probabilities; subsection 196B(8) for certain defence‑service claims; and subsection 196B(14) for claims under the MRCA. This instrument specifically repeals the 2014 instrument that was made under both subsections 196B(3) and (8) of the VEA. The new instrument is made only under subsection 196B(3), which may reflect a change in the coverage of the standard.

Section 11 of the instrument incorporates by reference other Statements of Principles. If a factor in section 9 refers to an injury or disease for which a Statement of Principles exists, then the factors of that other instrument apply. For example, factor 9(7) requires “organ or tissue transplantation”. If the transplantation was performed for end‑stage renal disease, and the Repatriation Medical Authority has a Statement of Principles concerning renal disease, the factors of that statement become relevant to the claim. This creates a cascading causation chain that can multiply the factual issues.

The instrument also interacts with the ICD‑10‑AM classification system. While the code C73 is given for identification, subsection 7(3) states that the meaning of malignant neoplasm is that in subsection 7(2), not the ICD code. That prevents a rigid statistical classification from overriding the clinical definition. However, the code may affect how the condition is recorded in hospital or death records, which may be used as evidence.

The instrument must be read with the relevant service definitions in the VEA and MRCA. Those definitions are not fully reproduced; the instrument gives only the categories relevant to it. A person who has operational service under the VEA is expressly excluded from “relevant service” under this instrument. That means they cannot use the balance of probabilities standard for that service. They would use the reasonable hypothesis standard and the corresponding Statement of Principles made under subsection 196B(2). This interaction can create a situation where a veteran has multiple periods of service, some covered by one standard and some by another, and the decision‑maker must separate the contributions.

The instrument does not interact with state workers’ compensation laws, nor with general tort law. It is a federal statutory scheme exclusive in nature.

This instrument is the second version of the Statement of Principles concerning malignant neoplasm of the thyroid gland on the balance of probabilities standard. It repeals the Statement of Principles No. 40 of 2014, which was made under subsections 196B(3) and (8) of the VEA. The earlier instrument took effect in 2014 and is identified in the repeal section by its Federal Register of Legislation number F2014L00478. The new instrument is made only under subsection 196B(3), suggesting a narrowing of the legal base, possibly because subsection 196B(8) is no longer applicable for this condition or because the Authority now considers the balance of probabilities standard sufficient.

The instrument does not include an explanatory memorandum or a statement of reasons for the changes from the 2014 version. The Authority simply states at section 8 that it has considered the sound medical‑scientific evidence and formed the view that a relationship is more probable than not. No new research or specific studies are cited. The changes in the factors are not itemised, but a comparison with the 2014 instrument (not provided in the source) would be needed to identify them. The instrument is a standalone document and does not cross‑reference any amendment history beyond the repeal.

The commencement date is 30 May 2022. The instrument does not contain a sunset clause or a review date. However, the Authority typically reviews Statements of Principles periodically as new evidence emerges. The five‑year gap between the 2014 and 2022 versions is typical. The instrument is a disallowable legislative instrument under the Legislation Act 2003, meaning it must be tabled in Parliament and may be disallowed by either House. The source does not indicate whether disallowance occurred.

The instrument itself does not cite any litigation history, and no cases are mentioned in its text. As a legislative instrument, it is not itself the subject of litigation; rather, it is applied in decisions that may be reviewed. The predecessor instrument (No. 40 of 2014) may have been considered in Administrative Appeals Tribunal or Federal Court decisions concerning thyroid cancer claims, but the source provides no information on that. The instrument is used at the first instance decision‑making level, and any judicial consideration of its meaning would be on questions of law, such as whether the Authority properly considered the evidence or whether the factors are ultra vires the VEA.

The instrument’s definitions and factors can be expected to be litigated on points of construction. For example, the phrase “at the time of the clinical onset” in factor 9(5) may give rise to disputes about when a thyroid condition first emerged relative to the cancer. The term “clinical onset” is not defined in the instrument, so it must be given its ordinary medical meaning, which can be contentious. Similarly, the calculation of cumulative equivalent dose using the ARPANSA guide may be challenged if the guide is ambiguous.

The instrument does not create a private right of action. A claimant cannot sue the Commonwealth for breaching the instrument; the remedy is administrative review. The litigation history of similar Statements of Principles typically involves veterans arguing that the factor threshold is too high or that the Authority ignored relevant science. The Federal Court has occasionally set aside a Statement of Principles for failure to take into account a relevant consideration or for making an irrational finding. However, such outcomes are rare, and the Court generally defers to the Authority’s expertise.

Several aspects of this instrument can trap the unwary.

First, the definition of relevant service is narrower than many expect. It excludes operational service, hazardous service, and British nuclear test defence service. A veteran who served in a combat zone and developed thyroid cancer cannot use this instrument. They must use the reasonable hypothesis standard, which has its own Statement of Principles (likely No. 39 of 2022 or similar). A practitioner who assumes this instrument applies across the board will misadvise the client.

Second, factor 9(4) requires obesity for at least 10 years before the clinical onset. The 10‑year period is strict. Even if a veteran was obese for nine years and 11 months before the cancer appeared, the factor is not met. Moreover, “being obese” is defined solely by BMI of 30 or greater. A muscular individual with a high BMI due to lean mass would be classified as obese, which could be a windfall for such a claimant, but a person with a normal BMI but high body fat percentage (e.g., “skinny fat”) would not qualify, even if their fat distribution increased cancer risk. The instrument does not adopt any measure of visceral adiposity or waist circumference.

Third, the cumulative equivalent dose calculation is fixed to an external ARPANSA guide as in force on 2 August 2017. If the science of dose calculation has advanced since then, the method may be outdated. The guide itself is not reproduced, so decision‑makers must locate it. The note lists examples of exposure sources but does not limit them. A veteran who was a flight attendant or pilot in peacetime service may argue cosmic radiation exposure, but the dose reconstruction may be complex and expensive.

Fourth, factor 9(8) concerning inability to obtain appropriate clinical management is limited by section 10(2) to cases where the condition existed before or during service but did not arise out of service. That factor is the only one that addresses aggravation, and it is not available for a condition that arose out of service. The term “appropriate clinical management” is not defined, leaving room for arbitrary denial or acceptance.

Fifth, the instrument excludes medullary thyroid carcinoma from the definition of malignant neoplasm. Medullary carcinoma is a separate disease with a different aetiology (often MEN2 syndromes). A claimant with medullary carcinoma cannot use this instrument at all. They may have to rely on a genetic link to service if they can prove exposure to a mutagen, but no factor in this instrument covers that.

Sixth, the definition of specified list of thyroid conditions includes goitre, Graves disease, Hashimoto thyroiditis, hyperthyroidism, and thyrotoxicosis. It does not include thyroid nodules of uncertain significance, thyroiditis other than Hashimoto, or subclinical hypothyroidism. A claimant with a benign nodule that later turned malignant would not satisfy factor 9(5) unless the nodule was diagnosed as one of those conditions.

Seventh, the instrument uses the balance of probabilities standard, but it does not specify the standard of proof for the factors themselves. In practice, each factor must be proved on the balance of probabilities. However, the “cumulative equivalent dose” factor requires a precise numerical threshold. Proving a dose of 0.5 Sv to the thyroid with certainty may be impossible for historical exposures; the decision‑maker may need to rely on modelling, which introduces uncertainty.

Eighth, the note to the cumulative equivalent dose definition says that dose is an average over the mass of the specific tissue. That means if the thyroid mass varies (e.g., due to goitre), the average dose may change. A small thyroid receiving a localised dose might have a higher average than a larger thyroid receiving the same total energy. This could work for or against the claimant.

Ninth, the factor for iodine‑131 therapy (factor 9(3)) requires that the therapy be received at least 5 years before the clinical onset. If a veteran received radioactive iodine for hyperthyroidism and the cancer was diagnosed 4 years later, the factor fails, even if the cancer is biologically linked to the therapy. The five‑year latency is a bright line.

Tenth, the instrument does not have a factor for family history or genetic syndromes (such as MEN2, Cowden syndrome, or familial adenomatous polyposis). If a veteran has a strong family history of thyroid cancer but no other factor, they cannot rely on this instrument. They would have to argue that the genetic condition itself arose from service, which is difficult.

For a claimant seeking to establish service connection for malignant neoplasm of the thyroid gland under the balance of probabilities standard, compliance with this instrument means producing evidence that at least one of the eight factors in section 9 exists and that the factor is related to the person’s relevant service.

Step 1: Confirm service type. Ensure the veteran or member’s service falls within the definition of “relevant service” in the Schedule 1 Dictionary: eligible war service (non‑operational), defence service (non‑hazardous), or peacetime service under the MRCA. If the service is operational, hazardous, or British nuclear test defence service, this instrument does not apply; use the reasonable hypothesis instrument instead.

Step 2: Confirm the diagnosis. The cancer must be a primary malignant neoplasm arising from follicular epithelial cells. Obtain a pathology report or oncology letter that specifies the histological type. If the diagnosis is medullary thyroid carcinoma, lymphoma, or sarcoma, this instrument cannot be used. If the diagnosis is papillary, follicular, Hurthle cell, anaplastic, mixed medullary‑follicular, or of uncertain malignant potential, it is covered.

Step 3: Gather evidence for each potential factor. The most commonly relevant factors are ionising radiation (factors 1 and 2) and obesity (factor 4). For radiation, obtain service records showing potential exposure (e.g., nuclear tests, X‑rays, or aircrew duties) and calculate the cumulative equivalent dose to the thyroid using the ARPANSA guide. The calculation must show a dose of at least 0.5 Sv for factor 1, or 0.1 Sv for factor 2 if the exposure occurred by age 20. For obesity, obtain medical records showing height and weight measurements over time. A body mass index of 30 or greater must be documented at least 10 years before the first clinical onset of the cancer. If the claimant had a prior thyroid condition (goitre, Graves, Hashimoto, hyperthyroidism, or thyrotoxicosis), obtain medical evidence of that diagnosis. For acromegaly or organ transplantation, obtain specialist reports.

Step 4: Establish the temporal relationship. Each factor has a specific latency period: at least 10 years for radiation factor 1, 5 years for radiation factor 2 and iodine therapy, 10 years for obesity, and the existence of a thyroid condition or acromegaly before clinical onset for factors 5 and 6. Factor 7 (transplantation) requires the transplant to occur before onset, with no stated minimum latency. Factor 8 (inability to obtain appropriate clinical management) applies only if the cancer existed before or during service and was aggravated by lack of proper care.

Step 5: Relate the factor to service. Under section 10(1), the factor must be related to the person’s relevant service. For example, if the claimant was exposed to ionising radiation during a diagnostic X‑ray while in service, that exposure must be documented. If the exposure occurred after service (e.g., civilian medical treatment), it does not qualify unless it is connected to service in some other way (e.g., a service‑related injury necessitating the X‑ray). The decision‑maker will look for a causal or contributory link between the factor and the service.

Step 6: Consider other applicable Statements of Principles. If the factor refers to another injury or disease (e.g., “organ or tissue transplantation” may be for a kidney disease covered by another SoP), comply with the factors in that other SoP as well. This may require meeting additional causation requirements.

Step 7: Prepare a statement or report. The claimant should provide a written statement explaining the temporal sequence and the link to service. Medical experts may need to provide reports addressing the specific definitions (e.g., that BMI was 30 or greater at the relevant time). For radiation, a health physicist may need to reconstruct the dose.

Step 8: File the claim. The claim is made under the VEA or MRCA. The decision‑maker will assess the evidence against this instrument. If the evidence satisfies one factor and the relationship to service, the condition is deemed service‑related. If not, the claim is refused, with reasons.

For legal practitioners, compliance means checking each factor systematically and not relying on medical opinion that does not reference the instrument’s definitions. The risk is that a well‑founded claim may fail because the evidence was not packaged to meet the bright‑line thresholds (e.g., 0.5 Sv, 10 years obesity). The instrument rewards meticulous record‑keeping and expert dosimetry.